Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
Molteni A, Riva M, Ravano E, Marbello L, Mancini V, Grillo G, Zucchetti E, Greco R, Cairoli R. Molteni A, et al. Int J Hematol. 2017 Jun;105(6):769-776. doi: 10.1007/s12185-017-2198-0. Epub 2017 Feb 20. Int J Hematol. 2017. PMID: 28220349
Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.
Cesana C, Klersy C, Brando B, Nosari A, Scarpati B, Scampini L, Molteni A, Nador G, Santoleri L, Formenti M, Valentini M, Mazzone A, Morra E, Cairoli R. Cesana C, et al. Among authors: molteni a. Leuk Res. 2008 Nov;32(11):1715-23. doi: 10.1016/j.leukres.2008.03.028. Epub 2008 May 5. Leuk Res. 2008. PMID: 18456323
Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the "International Working Group" criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience.
Molteni A, Riva M, Greco R, Nichelatti M, Ravano E, Marbello L, Nosari A, Morra E. Molteni A, et al. Int J Hematol. 2013 Apr;97(4):472-9. doi: 10.1007/s12185-013-1305-0. Epub 2013 Mar 19. Int J Hematol. 2013. PMID: 23508542
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta M, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. Molteni A, et al. Leuk Res. 2016 Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18. Leuk Res. 2016. PMID: 26852003
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.
Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A. Della Porta MG, et al. Among authors: molteni a. Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21. Leukemia. 2017. PMID: 28321120 Free PMC article.
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S. Voso MT, et al. Among authors: molteni a. Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154. Ann Oncol. 2017. PMID: 28368509 Free article. Clinical Trial.
225 results